Aarti Drugs Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n8kxkht2kz9y01qtz3fifsxa.pdf

Key Takeaways


Salicylic Acid: The Drag and the Thesis

Adhish Patil: "Had we been the stand-alone company, manufacturing only salicylic acid, it's going to be a problematic situation for us. But we have such a big product basket that the other products can easily absorb the loss of salicylic acid as of now."

Margin Bridge: Gross Margin Up, EBITDA Stuck

Adhish Patil: "had we had better utilization of the capacity, then probably our EBITDA margins would have been better, I mean, almost above 14.5% even with these gross margins."

Regulatory Re-entry and the US Tariff Tailwind

Adhish Patil: "And fortunately, this has come right when we got the USFDA approval back. So definitely, the customers might also feel -- the customers were solely dependent on China, will feel the need to approve more Indian sources."

Volume, Price and the Growth Algorithm


Capex Cycle: Heavy Spend, Long Payback


Guidance & Commitments

CommitmentSpecificsTimeline
Volume growth~15% YoY volume growthFY26 and FY27
Value growth5–6% in H1, ~10% or more in H2FY26
Value growth10–15% value growthFY27
Price variationNegative 4–6% YoY in H1, neutral from H2FY26
EBITDA margin15–16% achievable if everything goes right; last quarter of FY26 may attempt itFY27 annual; Q4 FY26 trial
Salicylic acid contributionBegin contributing to financialsQ3 FY26
Salicylic acid ramp-up800 tonnes/month very soon, then ~1,600 tonnes/monthNo date; breakeven at 1,500–1,600 tonnes
Sayakha commercializationTrial production started; targeting Q2Q2 FY26, may slip to Q3
US commercial suppliesThree products expected to launch; 9–12 months to commercial supplies~9–12 months from Q1 FY26
Formulation revenue target~₹550–₹600 croresFY28
Oncology R&D completion8–10 productsDecember 2026
New production blocks (Tarapur)Commissioning12–24 months
Full capex benefitOptimum utilization of all greenfield capex~FY28
Solar projectLower long-term power cost once fully operationalCommissioning in process

Key Metrics

MetricQ1 FY26
Total revenue₹591 cr, +6% YoY
Gross profit margin36.8%, +130 bps YoY
EBITDA₹74 cr, +12% YoY
EBITDA margin12.6%
API business revenue growth+5% YoY
Formulation business revenue₹80 cr, +14% YoY
Formulation export share57% of formulation revenue
Volume growth (standalone)~9% YoY
Negative price variation~4.5% YoY
Capex incurred₹48.5 cr (consolidated)
FY26 capex guidance₹150 cr to ₹200 cr
Net debt~₹597 cr (consolidated), 56% long-term, 44% working capital
Debt-to-equity ratio~0.42 to 0.43
Salicylic acid current outputbelow 200 tonnes per month
Salicylic acid ramp-up target800 tonnes per month near-term, expanding to ~1,600 tonnes per month